《大行報告》中金首予先瑞達醫療-B(06669.HK)「跑贏行業」評級 目標價23元
中金發表研報,首次給予先瑞達醫療-B(06669.HK)「跑贏行業」評級,指出公司深耕外周血管介入市場十多年,是動脈球囊領域的領導者和靜脈介入領域的先驅,截至今年6月在外周介入領域已有7個產品進入商業化階段,另外於五個全血管介入領域有26種產品正在研發階段,產品組合全面,反映出公司具有產品實力及強大平台化研發能力。
該行預期外周介入市場前景良好,估計該公司市場份額將持續提升,另外戰略投資有助促進增長,預測今明兩年經調整每股盈利將達到0.23及0.32元人民幣,給予目標價23元,對應2024年預測市盈率35倍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.